Get access

Polyclonal and monoclonal antibodies for induction therapy in kidney transplant recipients

  • Protocol
  • Intervention

Authors

  • Penny Morgan,

    Corresponding author
    1. Christchurch Public Hospital, Department of Nephrology, Christchurch, New Zealand
    Search for more papers by this author
  • Nicholas B Cross,

    1. Christchurch Public Hospital, Department of Nephrology, Christchurch, New Zealand
    Search for more papers by this author
  • A Nicholas R Barnett,

    1. Guy's and St Thomas' NHS Foundation Trust, Renal & Transplant Department, London, UK
    Search for more papers by this author
  • Jonathan C Craig,

    1. University of Sydney, Sydney School of Public Health, Sydney, NSW, Australia
    2. The Children's Hospital at Westmead, Cochrane Renal Group, Centre for Kidney Research, Westmead, NSW, Australia
    Search for more papers by this author
  • Angela C Webster

    1. University of Sydney, Sydney School of Public Health, Sydney, NSW, Australia
    2. The Children's Hospital at Westmead, Cochrane Renal Group, Centre for Kidney Research, Westmead, NSW, Australia
    3. University of Sydney at Westmead, Centre for Transplant and Renal Research, Westmead Millennium Institute, Westmead, NSW, Australia
    Search for more papers by this author

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

  • To evaluate the relative and absolute effects of different antibody preparations (except IL2Ra) when used as induction therapy in kidney transplant recipients.

  • To determine how the benefits and adverse events vary for each antibody preparation.

  • To determine how the benefits and harms vary for different formulations of antibody preparation.

  • To determine whether the benefits and harms vary in specific subgroups of recipients (e.g. children and sensitised recipients).